Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

XOMA Royalty Corporation - 8.625% Series A Cumulative Perpetual Preferred Stock (NQ:XOMAP)

25.85 -0.20 (-0.77%)

Streaming Delayed Price Updated: 1:27 PM EST, Feb 10, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	498
Open	26.02
Bid (Size)	25.85 (200)
Ask (Size)	26.28 (200)
Prev. Close	26.05
Today's Range	25.85 - 26.02
52wk Range	24.96 - 30.00
Shares Outstanding	N/A
Dividend Yield	8.34%

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

XOMA Royalty Announces Closing of Tender Offer and Completed Acquisition of Generation Bio, Inc.

February 09, 2026

Generation Bio Stockholders Received $4.2913 Per Share in Cash Plus a Contingent Value Right

From XOMA Royalty Corporation

Via GlobeNewswire

XOMA Royalty Announces CFO Transition

January 12, 2026

From XOMA Royalty Corporation

Via GlobeNewswire

Performance

YTD	-4.6%	-4.6%
1 Month	-1.5%	-1.5%
3 Month	-2.1%	-2.1%
6 Month	+0.6%	+0.6%
1 Year	+0.1%	+0.1%

More News

XOMA Royalty and Takeda Execute Strategic Royalty Sharing Transaction and Amend Existing Agreement for Mezagitamab

December 30, 2025

From XOMA Royalty Corporation

Via GlobeNewswire

XOMA Royalty Declares Quarterly Preferred Stock Dividends

December 22, 2025

From XOMA Royalty Corporation

Via GlobeNewswire

XOMA Royalty Announces Closing of Transaction to Acquire Mural Oncology plc

December 05, 2025

From XOMA Royalty Corporation

Via GlobeNewswire

XOMA Royalty Announces Closing of Transactions to Acquire LAVA Therapeutics N.V.

November 21, 2025

From XOMA Royalty Corporation

Via GlobeNewswire

XOMA Royalty Reports Third Quarter and Year to Date 2025 Financial Results and Highlights Recent Business Achievements

November 12, 2025

From XOMA Royalty Corporation

Via GlobeNewswire

XOMA Royalty and LAVA Therapeutics Announce Amendment to Purchase Agreement

October 17, 2025

From XOMA Royalty Corporation; LAVA Therapeutics N.V.

Via GlobeNewswire

XOMA Royalty Extends Tender Offer to Acquire LAVA Therapeutics N.V.

October 02, 2025

From XOMA Royalty Corporation; LAVA Therapeutics

Via GlobeNewswire

XOMA Royalty Declares Quarterly Preferred Stock Dividends

September 22, 2025

From XOMA Royalty Corporation

Via GlobeNewswire

XOMA Royalty Announces Closing of Tender Offer for HilleVax, Inc.

September 17, 2025

From XOMA Royalty Corporation

Via GlobeNewswire

XOMA Royalty to Present at H.C. Wainwright 27th Annual Global Investment Conference

September 03, 2025

From XOMA Royalty Corporation

Via GlobeNewswire

Mural Oncology Announces Entry into Agreement to be Acquired by XRA 5 Corp., a wholly owned subsidiary of XOMA Royalty for between $2.035 and $2.24 in Cash per Share

August 20, 2025

From XOMA Royalty Corporation

Via GlobeNewswire

XOMA Royalty Reports Second Quarter and Year to Date 2025 Financial Results and Highlights Recent Business Achievements

August 13, 2025

From XOMA Royalty Corporation

Via GlobeNewswire

XOMA Royalty Announces Closing of Tender Offer for Turnstone Biologics

August 11, 2025

From XOMA Royalty Corporation

Via GlobeNewswire

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

August 07, 2025

Via Benzinga

XOMA Royalty Enters into Agreement to Acquire LAVA Therapeutics for Between $1.16 and $1.24 Per Share in Cash, Plus a Contingent Value Right

August 04, 2025

From XOMA Royalty Corporation; LAVA Therapeutics N.V.

Via GlobeNewswire

HilleVax Enters into a Definitive Agreement to be Acquired by XOMA Royalty for $1.95 in Cash per Share Plus a Contingent Value Right

August 04, 2025

From XOMA Royalty Corporation

Via GlobeNewswire

Turnstone Biologics Corp. Enters into Agreement to be Acquired by XOMA Royalty Corporation for $0.34 in Cash Per Share Plus a Contingent Value Right

June 27, 2025

From XOMA Royalty Corporation; Turnstone Biologics Corp.

Via GlobeNewswire

XOMA Royalty Declares Quarterly Preferred Stock Dividends

June 18, 2025

From XOMA Royalty Corporation

Via GlobeNewswire

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

June 11, 2025

Via Benzinga

XOMA Royalty Purchases Mezagitamab Royalty and Milestone Rights Held by BioInvent International for up to USD $30 Million

May 27, 2025

From XOMA Royalty Corporation; BioInvent

Via GlobeNewswire

XOMA Royalty Reports First Quarter 2025 Financial Results and Highlights Business Achievements

May 13, 2025

From XOMA Royalty Corporation

Via GlobeNewswire

XOMA Royalty to Present at H.C. Wainwright 1st Annual Royalty Company Virtual Conference

May 07, 2025

From XOMA Royalty Corporation

Via GlobeNewswire

XOMA Royalty Completes Sale of Kinnate Pipeline Assets

April 14, 2025

From XOMA Royalty Corporation

Via GlobeNewswire

Frequently Asked Questions

Is XOMA Royalty Corporation - 8.625% Series A Cumulative Perpetual Preferred Stock publicly traded?

Yes, XOMA Royalty Corporation - 8.625% Series A Cumulative Perpetual Preferred Stock is publicly traded.

What exchange does XOMA Royalty Corporation - 8.625% Series A Cumulative Perpetual Preferred Stock trade on?

XOMA Royalty Corporation - 8.625% Series A Cumulative Perpetual Preferred Stock trades on the Nasdaq Stock Market

What is the ticker symbol for XOMA Royalty Corporation - 8.625% Series A Cumulative Perpetual Preferred Stock?

The ticker symbol for XOMA Royalty Corporation - 8.625% Series A Cumulative Perpetual Preferred Stock is XOMAP on the Nasdaq Stock Market

What is the current price of XOMA Royalty Corporation - 8.625% Series A Cumulative Perpetual Preferred Stock?

The current price of XOMA Royalty Corporation - 8.625% Series A Cumulative Perpetual Preferred Stock is 25.85

When was XOMA Royalty Corporation - 8.625% Series A Cumulative Perpetual Preferred Stock last traded?

The last trade of XOMA Royalty Corporation - 8.625% Series A Cumulative Perpetual Preferred Stock was at 02/10/26 01:27 PM ET

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.